Chaemin Lim

Coiled is a clinical-stage precision oncology company pioneering next-generation cancer therapeutics by targeting key driver node pathways. AO-252, our lead candidate, is a first-in-class, orally available, small molecule TACC3 inhibitor.

• Lead the scientific and strategic direction of a clinical-stage biotech utilizing a proprietary AI-driven drug design platform (SCULPT™) to develop novel therapeutics for life-threatening diseases. • Provide comprehensive leadership across scientific, programmatic, operational, and financial functions to advance A2A’s pipeline and technology platform. • Oversee the progression of multiple drug programs from target validation through IND-enabling studies and into early clinical development. • Direct cross-functional internal teams and global CROs, ensuring data-driven decision-making across medicinal chemistry, biology, and DMPK functions. • Drive continuous innovation and expansion of A2A’s platform capabilities, while strengthening the company’s intellectual property portfolio. • Negotiated and secured a major partnership with a Korean pharmaceutical company (2020), including upfront and milestone payments, with future potential for clinical/commercial milestones, royalties, and joint venture opportunities. • Spearheaded scientific due diligence and played a key role in strategic BD engagements with pharma partners and investors.

Advisor: Dr. Peter Wipf • Designed mitochondria-targeted ROS generators and improved JP4 analogs for radiation mitigation. • Developed affinity-tagged and biotin-conjugated AZD6738 analogs to explore ATR inhibition mechanisms. • Multiple patents resulting from this work have been licensed to industry partners. • Collaborated with multidisciplinary teams across research areas.

PI: Dr. Donna Huryn • Led medicinal chemistry efforts for NIH/NCI Chemical Biology Consortium programs. • Developed novel inhibitors for targets including p97, ATG4b, and Artemis through structure- and ligand-based design. • Built a 300-compound Mercaptophile Library and synthesized key analogs from HTS hits to support lead optimization. • Actively collaborated with team members and CROs, supporting synthesis of key intermediates and providing optimized synthetic routes.

Advisor: Dr. Sanghee Kim Research on small molecule and chemical probe synthesis • Synthesized small molecules and chemical probes, including a solid-supported chemodosimetric fluorescent probe. • Co-authored patents and research grants; mentored students and collaborated with international research partners on various interdisciplinary projects. • Contributed to multiple licensed patents stemming from novel therapeutic designs.

Integrated MA/Ph.D. in Synthetic and Medicinal Chemistry Adviser: Dr. Sanghee Kim • Dissertation - Part A. Efficient and Stereoselective Synthesis of (+)-MK7607 and its C-1 Epimer via the Transposition of a Tertiary Allylic Alcohol. Part B. Synthesis and Evaluation of Novel Artificial Nucleic Acids as a New Class of Biomolecules. • Research directed toward bioactive compounds inspired by natural product especially focusing on the construction of small molecule libraries. • Synthetic methodology development, peptidomimetics, and small natural product synthesis. • Research toward novel treatments for multiple therapeutic areas by using computation tools especially with docking simulation. • Accomplishments include: 14 SCI papers and 6 patent publication/application

• Professional license: Registered Pharmacist (March 2006, South Korea).